ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Basic/Clinical Science Session

SGLT2 Inhibition for CKD: Results of the DAPA-CKD Trial

October 23, 2020 | 02:30 PM - 03:30 PM

Location: Live-Streamed

Session Description

The DAPA-CKD trial assessed the SGLT2 inhibitor dapagliflozin on kidney and cardiovascular events in participants with CKD with and without type 2 diabetes (T2D). The trial was stopped early for overwhelming efficacy. This session presents the results of the DAPA-CKD trial with a focus on patients without T2D.

Learning Objective(s)

  • Discuss mechanisms of action of SGLT2 inhibitors in patients with and without T2D
  • Describe the DAPA-CKD trial design and highlight differences from other trials
  • Discuss the DAPA-CKD trial results with a focus on patients without T2D

Learning Pathway(s)

  • Chronic Kidney Disease
  • Diabetes and Metabolism


  • Meg J. Jardine, MBBS, PhD


  • Rationale and Design of the DAPA-CKD Trial
    02:30 PM - 02:50 PM
    Hiddo Jan L Heerspink, PhD 
  • Results of the DAPA-CKD Trial
    02:50 PM - 03:10 PM
    David C. Wheeler, MD
  • Clinical Perspective on the DAPA-CKD Trial
    03:10 PM - 03:30 PM
    Robert D. Toto, MD